Tigemonam 

Tigemonam is a monobactam, with potent activity against Gram-negative aerobic bacterial pathogens.

Tigemonam (0.25 mg/L) inhibits 90% of Escherichia coli, Klebsiella spp., Proteus spp., Salmonella spp., Haemophilus influenzae and Branhamella catarrhalis tested. The MIC₉₀ for Enterobacter spp. is 16 mg/L and for Citrobacter 4 mg/L. Pseudomonas aeruginosa is resistant to tigemonam but susceptible to aztreonam. Tigemonam shows minimal inoculum dependence, between 10² and 10⁶ cfu per spot^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tigemonam shows potent activities against Escherichia coli SC 8294, E. coli SC 12199, Salmonella schottmulleri SC 3850, Proteus mirabilis SC 9575, Providencia rettgeri SC 8217, Klebsiella pneumoniae SC 12216, Serratia marcescens SC 9782, Enterobacter cloacae SC 11078, Haemophilus influenzae SC 10556, with ED₅₀ of 1.4 mg/kg, 1.5 mg/kg, 0.7 mg/kg, 0.3 mg/kg, 0.2 mg/kg, 0.9 mg/kg, 0.5 mg/kg, 3.9 mg/kg and 1.8 mg/kg in mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

437.41

C₁₂H₁₅N₅O₉S₂

102507-71-1

OC(CO/N=C(C1=CSC(N)=N1)\C(N[C@H]2C(C)(N(OS(=O)(O)=O)C2=O)C)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Rylander M, et al. Comparative in-vitro activity of tigemonam, a new monobactam. J Antimicrob Chemother. 1988 Sep;22(3):307-13.  [Content Brief]

  [2]. Clark JM, et al. In vivo evaluation of tigemonam, a novel oral monobactam. Antimicrob Agents Chemother. 1987 Feb;31(2):226-9.  [Content Brief]